Barry Holtz
Dr. Barry Holtz has 30 years of experience in the development of bioproducts and biopharmaceuticals. Serving 15 years as Senior Vice President of Biopharmaceutical Development for Large Scale Biology Corporation, Dr. Holtz was responsible for the product development, clinical development and manufacturing compliance of the company's proprietary therapeutics portfolio. These projects included leading development and manufacturing teams that successfully brought a recombinant, plant-made, patient specific vaccine for treatment of indolent Non-Hodgkin's lymphoma, from the bench to human clinical trials. Dr. Holtz was also responsible for the design, construction and commissioning of the LSBC biopharmaceutical production facility in Owensboro, Kentucky and two other bioproducts facilities for other companies.
Prior to Large Scale Biology, Dr. Holtz was the founder and President of Holtz Bio-Engineering. Over its nine-year history, the company was involved in the development of bioreactor-based processes for the biotechnology sector and developed a proprietary line of bioreactors and distributed logic control systems for cell culture. Holtz Bio-Engineering was merged into Large Scale Biology in 1989.
Dr. Holtz has held research management positions at Foremost-Mckesson and was on the faculty of Ohio State University. He received his Ph.D. at Pennsylvania State University and was an NSF Postdoctoral Fellow at Scripps Institution of Oceanography. Dr. Holtz has been awarded 22 US patents and has published over 40 scientific papers. In 2003, Dr. Holtz received the Outstanding Alumni Award from Pennsylvania State University.